ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

India's Lupin targets generic potential of biotech drugs

Expiring patents open window for launch in Japan and Europe by year end

A worker conducts an inspection at Lupin's biosimilar plant in Pune, India. (Photo courtesy of Lupin)

MUMBAI -- India's third-largest drugmaker by sales, Lupin, has diversified into biosimilars -- cheaper versions of expensive biotech drugs -- in a bid to stimulate growth amid a slowdown in recent years.

Lupin plans to supplement its traditional business in generics and specialty drugs with biosimilars slated for launch in Japan, Europe and other markets by the end of the year, Lupin Biotech President Cyrus Karkaria told the Nikkei Asian Review.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more